Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report

by Po-Lan Su, MD, Chien-Yu Lin, MD, Yi-Lin Chen, MS, Wan-Li Chen, MS, Chien-Chung Lin, MD, PhD, Wu-Chou Su, MD
Published 2021-08-01

Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors

by Keunchil Park, MD, PhD, Daniel Shao Weng Tan, BSc, M.B.B.S., MRCP, Wu-Chou Su, MD, Byoung Chul Cho, MD, PhD, Sang-We Kim, MD, PhD, Ki Hyeong Lee, MD, PhD, Chin-Chou Wang, MD, MS, Takashi Seto, MD, Dennis Chin-Lun Huang, MD, Helen Hayoun Jung, BS, RPh, Ming-Chi Hsu, PhD, Thomas Bogenrieder, MD, PhD, Chia-Chi Lin, MD, PhD
Published 2021-09-01

Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study

by James Chih-Hsin Yang, MD, PhD, Karen L. Reckamp, MD, Young-Chul Kim, MD, PhD, Silvia Novello, MD, PhD, Egbert F. Smit, MD, PhD, Jong-Seok Lee, MD, PhD, Wu-Chou Su, MD, Wallace L. Akerley, MD, Collin M. Blakely, MD, PhD, Harry J.M. Groen, MD, PhD, Lyudmila Bazhenova, MD, Enric Carcereny Costa, MD, Rita Chiari, MD, PhD, Te-Chun Hsia, MD, PhD, Tony Golsorkhi, MD, Darrin Despain, MStat, Danny Shih, BA, Sanjay Popat, BSc, MBBS, FRCP, PhD, Heather Wakelee, MD
Published 2021-02-01